{"id":6059,"date":"2022-04-01T16:26:21","date_gmt":"2022-04-01T08:26:21","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=6059"},"modified":"2022-04-01T16:26:21","modified_gmt":"2022-04-01T08:26:21","slug":"eisai-announcesacquisition-of-arteryexshares-making-arteryexa-subsidiary-to-strengthen-and-rapidly-expand-the-foundation-of-its-digital-solution-business","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/en\/2022\/04\/01\/eisai-announcesacquisition-of-arteryexshares-making-arteryexa-subsidiary-to-strengthen-and-rapidly-expand-the-foundation-of-its-digital-solution-business\/","title":{"rendered":"Eisai AnnouncesAcquisition of ArteryexShares (Making Arteryexa Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business"},"content":{"rendered":"
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc. (Headquarters: Tokyo, CEO: Li Dongying, \u201cArteryex\u201d), a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. The two companies will work together to develop and provide PHR (Personal Health Record)-related services for patients, healthcare professionals and society at large.<\/p>\n
<\/p>\n
Eisai launched its medium-term business plan \u201cEWAY Future & Beyond\u201d in April 2021, where the perspective to be shifted from that of patients to The People or each consumer. With \u201cempowering The People to realize their fullest life\u201d as the vision, Eisai delivers not only pharmaceutical products but also solutions to The People, by utilizing the latest digital technology such as AI, and aims to remove the anxiety of The People.<\/p>\n
Arteryex has excellent software development capabilities and has developed its own PHR-related product services, including apps for storing and converting health-related information of patients undergoing treatment and a wide range of users into data, as well as apps for companies for employee health management.<\/p>\n
<\/p>\n
Eisai aims to strengthen and rapidly expand its digital solution business base by acquiring Arteryex’s development capabilities and quality PHR products through the subsidiary acquisition. In addition to reaching a new customer segment of existing products, Eisai will promote developing products including new applications by utilizing Arteryex\u2019s input technology and systems used in image data. Furthermore, Eisai will advance the utilization of data acquired through PHR-related products, as the entire Eisai Group, leveraging the data management know-how that Eisai has practiced in its medicine creation activities and disease awareness activities.<\/p>\n
For building the Eisai Universal Platform (EUP), through those initiatives, Eisai will enhance creating a packaged solution, as well as strengthen its delivery infrastructure, for maintenance and improvement of health, prevention and disease awareness, and will expand its contribution to The People.<\/p>\n
<\/p>\n
The current management team of Arteryex will remain after the conversion to a subsidiary. The acquisition by Eisai of Arteryex as a subsidiary will not have a material impact on the consolidated financial results of Arteryex.<\/p>\n
\n
Media Inquiries:<\/span><\/p>\n Public Relations Department,<\/p>\n Eisai Co., Ltd.<\/p>\n +81-(0)3-3817-5120<\/p>\n <\/p>\n <\/p>\n [Notes to editors]<\/b><\/p>\n 1. About Arteryex Inc.<\/b><\/p>\n Arteryex is a software planning and development company specializing in systems and application software in the medical and healthcare fields. In the era of 100 years of life, it is becoming increasingly important for people to stay healthy. On the other hand, the data needed to advance medical care is fragmented and dispersed in various fields. The company\u2019s goal is to better understand the needs of each individual and to achieve optimal health care and medical treatment for each person with combining the latest technologies, such as blockchain and AI, to maximize the use of data that is currently underutilized.<\/p>\n \n Outline of Arteryex<\/p>\n <\/p>\n <\/p>\n\n
\n Company Name:<\/td>\n Arteryex Inc.<\/td>\n<\/tr>\n \n Location:<\/td>\n 1-4-4, Iwamoto-cyo, Chiyoda-ku, Tokyo, Japan<\/td>\n<\/tr>\n \n Representative:<\/td>\n Li Dongying<\/td>\n<\/tr>\n \n Principal Businesses:<\/td>\n Software planning and development<\/td>\n<\/tr>\n \n Capital:<\/td>\n 32 million yen<\/td>\n<\/tr>\n \n Foundation:<\/td>\n March, 2018<\/td>\n<\/tr>\n \n Number of Employees:<\/td>\n 19<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n